(Total Views: 411)
Posted On: 05/17/2021 7:17:29 PM
Post# of 148939
Re: Evil Rabbit #90586
Philippines (FDA), Brazil (Albert Einstein), Macleod (India) all have seen the U.S. CD10 & CD12 trial results...and clearly see what the FDA refuses to...that Leronlimab has great potential to serve in the fight against COVID-19 for the sickest patients.
I tend to agree with you #EvilRabbit...I do not see this letter from the FDA taking them off course from impartially testing and reviewing the effectiveness of Leronlimab in Covid-19. i.e. FDA's position on Leronlimab in today's letter is nothing new to them.
I tend to believe that the FDA have themselves in a corner with Leronlimab with: their own protocols; reliance on P values; turning down the "4 Dose" protocol at the outset (and perhaps for CD18); failure to disclose today that Cytodyn has filed a follow-up study based upon the learnings (Age, 4 Dose...), failure to see in the interim review or request to see the interim CD-12 results (and missed or did not see the age imbalance).
I firmly believe in the science of Leronlimab, the data & the lives saved. Cytodyn has great momentum elsewhere and this defensive play by the FDA will be seen for what it is soon enough.
GLTA
GLTA
I tend to agree with you #EvilRabbit...I do not see this letter from the FDA taking them off course from impartially testing and reviewing the effectiveness of Leronlimab in Covid-19. i.e. FDA's position on Leronlimab in today's letter is nothing new to them.
I tend to believe that the FDA have themselves in a corner with Leronlimab with: their own protocols; reliance on P values; turning down the "4 Dose" protocol at the outset (and perhaps for CD18); failure to disclose today that Cytodyn has filed a follow-up study based upon the learnings (Age, 4 Dose...), failure to see in the interim review or request to see the interim CD-12 results (and missed or did not see the age imbalance).
I firmly believe in the science of Leronlimab, the data & the lives saved. Cytodyn has great momentum elsewhere and this defensive play by the FDA will be seen for what it is soon enough.
GLTA
GLTA
(3)
(1)Scroll down for more posts ▼
